IL226667A - Histone inhibitors - Google Patents

Histone inhibitors

Info

Publication number
IL226667A
IL226667A IL226667A IL22666713A IL226667A IL 226667 A IL226667 A IL 226667A IL 226667 A IL226667 A IL 226667A IL 22666713 A IL22666713 A IL 22666713A IL 226667 A IL226667 A IL 226667A
Authority
IL
Israel
Prior art keywords
histone
inhibition
histone inhibition
Prior art date
Application number
IL226667A
Other languages
English (en)
Hebrew (he)
Inventor
Wentworth Stephens Ross
Richard Parish Christopher
Geoffrey Freeman Craig
John Senden Timothy
Original Assignee
Univ Australian National
Wentworth Stephens Ross
Richard Parish Christopher
Geoffrey Freeman Craig
John Senden Timothy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Australian National, Wentworth Stephens Ross, Richard Parish Christopher, Geoffrey Freeman Craig, John Senden Timothy filed Critical Univ Australian National
Publication of IL226667A publication Critical patent/IL226667A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
IL226667A 2010-12-01 2013-05-30 Histone inhibitors IL226667A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41882610P 2010-12-01 2010-12-01
PCT/AU2011/001550 WO2012071611A1 (en) 2010-12-01 2011-11-29 Histone inhibition

Publications (1)

Publication Number Publication Date
IL226667A true IL226667A (en) 2017-02-28

Family

ID=46171086

Family Applications (1)

Application Number Title Priority Date Filing Date
IL226667A IL226667A (en) 2010-12-01 2013-05-30 Histone inhibitors

Country Status (15)

Country Link
US (1) US9226939B2 (enExample)
EP (1) EP2646037B1 (enExample)
JP (2) JP2014501730A (enExample)
KR (1) KR101956335B1 (enExample)
CN (1) CN103402526B (enExample)
AU (1) AU2011335881B2 (enExample)
BR (1) BR112013013544B1 (enExample)
CA (1) CA2819642C (enExample)
DK (1) DK2646037T3 (enExample)
ES (1) ES2710857T3 (enExample)
HU (1) HUE043546T2 (enExample)
IL (1) IL226667A (enExample)
NZ (1) NZ611316A (enExample)
SG (1) SG190438A1 (enExample)
WO (1) WO2012071611A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3105593B2 (ja) 1991-10-18 2000-11-06 東海パルプ株式会社 パルパー制御装置
CN116622006B (zh) 2017-03-10 2025-05-30 北卡罗来纳大学查珀尔希尔分校 短效的基于肝素的抗凝血剂化合物和方法
WO2019010216A1 (en) 2017-07-03 2019-01-10 The University Of North Carolina At Chapel Hill ENZYMATIC SYNTHESIS OF HOMOGENEOUS CHONDROITIN SULFATE OLIGOSACCHARIDES
US11865137B2 (en) 2017-11-03 2024-01-09 The University Of North Carolina At Chapel Hill Sulfated oligosaccharides having anti-inflammatory activity
KR102753401B1 (ko) * 2017-12-15 2025-01-10 오스트레일리언 내셔널 유니버시티 세포외 히스톤 매개된 병리를 치료 및 예방하기 위한 화합물
US11633424B2 (en) * 2018-06-20 2023-04-25 The University Of North Carolina At Chapel Hill Cell protective methods and compositions
WO2020033824A1 (en) * 2018-08-09 2020-02-13 University Of Vermont And State Agricultural College Inhibitors of acute severe inflammatory conditions
KR20210132032A (ko) * 2019-02-25 2021-11-03 디 오스트레일리언 내셔널 유니버시티 Net 관련 합병증의 치료 및 예방용 화합물
CN114980904A (zh) 2019-11-13 2022-08-30 北卡罗来纳大学查珀尔希尔分校 硫酸乙酰肝素(hs)低聚糖在肝缺血再灌注损伤中的影响
WO2022116981A1 (zh) * 2020-12-01 2022-06-09 远大医药（中国）有限公司 一种聚阴离子纤维二糖苷类化合物的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4847338A (en) * 1985-03-28 1989-07-11 University Of Iowa Research Foundation Low molecular weight heparin fragments as inhibitors of complement activation
DK505488D0 (da) * 1987-12-21 1988-09-09 Bar Shalom Daniel Middel og anvendelse af samme
US5583121A (en) 1994-01-12 1996-12-10 Michigan State University Non-anticoagulant chemically modified heparinoids for treating hypovolemic shock and related shock syndromes
DK0703005T3 (da) 1994-09-21 2000-05-08 Allrad No 28 Pty Ltd En elektrostatisk udfælder
AUPN261895A0 (en) 1995-04-28 1995-05-18 Australian National University, The Preparation and use of sulfated oligosaccharides
WO1999004826A1 (en) 1997-07-24 1999-02-04 The Australian National University Method for detection of fibrin clots
ITMI20021294A1 (it) 2002-06-12 2003-12-12 Inalco Spa Polisaccaridi batterici o-solfatati e loro uso
US7468358B2 (en) * 2004-06-16 2008-12-23 Paringenix, Inc. Method and medicament for sulfated polysaccharide treatment of heparin-induced thrombocytopenia (HIT) syndrome
US20050282775A1 (en) 2004-06-16 2005-12-22 Paringenix, Inc. Method and medicament for sulfated polysaccharide treatment of inflammation without inducing platelet activation and heparin-induced thrombocytopenia syndrome
WO2006015171A2 (en) 2004-07-28 2006-02-09 The Texas A & M University System Use of glycosoaminoglycans for the prevention and treatment of sepsis
ES2434849T3 (es) 2005-04-29 2013-12-17 The Australian National University Método de formación de una composición radioactiva injectable de partículas radioactivas encapsuladas en carbono
EP1747785A1 (en) 2005-07-28 2007-01-31 Istituto Clinico Humanitas Cyclodextrins for blood detoxification
PT1954292E (pt) 2005-11-28 2014-08-04 Verrow Pharmaceuticals Inc Composições úteis para reduzir a nefrotoxicidade e métodos para a sua utilização
WO2007095688A1 (en) * 2006-02-23 2007-08-30 The Australian National University Methods for increasing the number of circulating cells
GB2450087A (en) * 2007-06-11 2008-12-17 Diosamine Dev Corp Use of sulphated saccharides in the treatment of inflammatory and/or auto-immune diseases
JP2011503012A (ja) 2007-11-06 2011-01-27 オクラホマ・メディカル・リサーチ・ファウンデーション 予後に関するバイオマーカーおよび治療の分子標的としての細胞外ヒストン
US9283291B2 (en) 2008-04-24 2016-03-15 The Australian National University Methods for radiolabeling macromolecules
JP2011256111A (ja) * 2008-10-03 2011-12-22 Hayashibara Biochem Lab Inc 敗血症の予防及び治療剤

Also Published As

Publication number Publication date
BR112013013544A2 (pt) 2016-10-11
US9226939B2 (en) 2016-01-05
CN103402526A (zh) 2013-11-20
KR20130121877A (ko) 2013-11-06
JP2014501730A (ja) 2014-01-23
NZ611316A (en) 2014-12-24
US20130338097A1 (en) 2013-12-19
BR112013013544B1 (pt) 2020-09-29
CA2819642C (en) 2019-07-16
WO2012071611A1 (en) 2012-06-07
KR101956335B1 (ko) 2019-03-08
CA2819642A1 (en) 2012-06-07
EP2646037A4 (en) 2015-03-18
AU2011335881B2 (en) 2016-07-14
SG190438A1 (en) 2013-07-31
AU2011335881A1 (en) 2013-06-20
EP2646037B1 (en) 2019-01-09
EP2646037A1 (en) 2013-10-09
JP2016193917A (ja) 2016-11-17
HUE043546T2 (hu) 2019-08-28
DK2646037T3 (en) 2019-03-04
ES2710857T3 (es) 2019-04-29
CN103402526B (zh) 2016-01-20
JP6142039B2 (ja) 2017-06-07

Similar Documents

Publication Publication Date Title
DK3342786T3 (en) Anti-dll3-antistof
AP3107A (en) 5-Alkynyl-pyrimidines
EP2566479A4 (en) AZA-INDAZOLES
GB201215746D0 (en) Rotocraft
HUE051199T2 (hu) Módosított anti-CD-4 antitestek
DK3466977T3 (en) Anti-vla-4-antistoffer
GB201013705D0 (en) Ramp
GB201113485D0 (en) Corrosion protection
GB201009853D0 (en) HSP90 inhibitors
GB201020798D0 (en) Corrosion inhibitors
SI2526230T1 (sl) Snežni plug
GB201014143D0 (en) Combinix
GB2482174B (en) Access ramp
SG10201508549UA (en) Modified tamavidin
GB201002945D0 (en) Access point
GB201018597D0 (en) Inhibitors
AU4932P (en) FlatwaxpinkGL Chamelaucium uncinatum
AU4536P (en) TB01 Tibouchina urvilleana
AU4931P (en) FlatwaxDarkGL Chamelaucium uncinatum
AU4937P (en) FlatinsulGL Myoporum insulare
GB201014190D0 (en) Enzyme inhibition
GB201014183D0 (en) Enzyme inhibition
GB201003936D0 (en) Novel inhibitors
GB201003502D0 (en) Novel inhibitors
GB201006605D0 (en) Novel inhibitors

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed